Acta Biomaterialia, Journal Year: 2024, Volume and Issue: unknown
Published: Oct. 1, 2024
Language: Английский
Nature Reviews Materials, Journal Year: 2023, Volume and Issue: 9(2), P. 100 - 118
Published: Dec. 22, 2023
Language: Английский
Citations
52
Acta Biomaterialia, Journal Year: 2023, Volume and Issue: 161, P. 1 - 36
Published: March 10, 2023
Language: Английский
Citations
24
ACS Nano, Journal Year: 2024, Volume and Issue: 18(13), P. 9413 - 9430
Published: March 24, 2024
Personalized in situ tumor vaccination is a promising immunotherapeutic modality. Currently, seeking immunogenic cell death (ICD) to generate vaccines still mired by insufficient immunogenicity and an entrenched immunosuppressive microenvironment (TME). Herein, series of tetrazine-functionalized ruthenium(II) sonosensitizers have been designed screened for establishing bioorthogonal-activated vaccine via oncolytic pyroptosis induction. Based on nanodelivery-augmented bioorthogonal metabolic glycoengineering, the original selectively remolded introduce artificial target bicycle [6.1.0] nonyne (BCN) into membrane. Through specific ligation with intratumoral BCN receptors, can realize precise membrane-anchoring synchronous click-activation desired sites. Upon ultrasound (US) irradiation, activated intensively disrupt membrane dual type I/II reactive oxygen species (ROS) generation high-efficiency sonodynamic therapy (SDT). More importantly, severe damage eminently evoke maximize reverse TME, ultimately eliciting powerful durable systemic antitumor immunity. The US-triggered certified effectively inhibit growths primary distant tumors, suppress metastasis recurrence "cold" models. This bioorthogonal-driven tumor-specific induction strategy has great potential development robust vaccines.
Language: Английский
Citations
15
ACS Nano, Journal Year: 2024, Volume and Issue: 18(19), P. 12194 - 12209
Published: May 1, 2024
In situ vaccines (ISVs) utilize the localized delivery of chemotherapeutic agents or radiotherapy to stimulate release endogenous antigens from tumors, thereby eliciting systemic and persistent immune activation. Recently, a bioinspired ISV strategy has attracted tremendous attention due its features such as an adjuvant effect genetic plasticity. M13 bacteriophages are natural nanomaterials with intrinsic immunogenicity, flexibility, cost-effectiveness for large-scale production, demonstrating potential application in cancer vaccines. this study, we propose based on engineered bacteriophage targeting CD40 (M13CD40) dendritic cell (DC)-targeted stimulation, named H-GM-M13CD40. We induce immunogenic death tumor through local (S)-10-hydroxycamptothecin (HCPT), followed by intratumoral injection granulocyte-macrophage colony stimulating factor (GM-CSF) M13CD40 enhance DC recruitment demonstrate that can result significant accumulation activation DCs at site, reversing immunosuppressive microenvironment. addition, H-GM-M13CD40 synergize PD-1 blockade abscopal effects cold models. Overall, our study verifies immunogenicity provides proof concept phage function ISVs.
Language: Английский
Citations
14
ACS Nano, Journal Year: 2024, Volume and Issue: 18(29), P. 18801 - 18833
Published: July 9, 2024
Tumor vaccines, an important part of immunotherapy, prevent cancer or kill existing tumor cells by activating restoring the body's own immune system. Currently, various formulations vaccines have been developed, including cell membrane DNA mRNA polypeptide virus-vectored and tumor-in-situ vaccines. There are also multiple delivery systems for such as liposomes, vesicles, viruses, exosomes, emulsions. In addition, to decrease risk escape tolerance that may exist with a single vaccine, combination therapy radiotherapy, chemotherapy, checkpoint inhibitors, cytokines, CAR-T therapy, photoimmunotherapy is effective strategy. Given critical role in here, we look back history discuss antigens, adjuvants, formulations, systems, mechanisms, future directions
Language: Английский
Citations
13
Advanced Materials, Journal Year: 2023, Volume and Issue: 35(52)
Published: Nov. 11, 2023
The immune response in cancer reflects a series of carefully regulated events; however, current tumor immunotherapies typically address single key aspect to enhance anti-tumor immunity. In the present study, nanoplatform (Fe3 O4 @IR820@CpG)-based immunotherapy strategy that targets multiple steps cancer-immunity cycle is developed: 1) promotes release tumor-derived proteins (TDPs), including tumor-associated antigens and pro-immunostimulatory factors), addition direct killing effect, by photothermal (PTT) photodynamic therapy (PDT); 2) captures released TDPs delivers them, together with CpG (a Toll-like receptor 9 agonist) antigen-presenting cells (APCs) promote antigen presentation T cell activation; 3) enhances tumor-killing ability combining anti-programmed death ligand 1 antibody (α-PD-L1), which collectively advances outstanding effects on colorectal, liver breast cancers. broad-spectrum activity Fe3 @IR820@CpG α-PD-L1 demonstrates optimally manipulating anti-cancer immunity not singly but as group provides promising clinical strategies.
Language: Английский
Citations
18
Gynecologic Oncology, Journal Year: 2024, Volume and Issue: 186, P. 77 - 84
Published: April 10, 2024
Language: Английский
Citations
8
Nano Today, Journal Year: 2024, Volume and Issue: 56, P. 102286 - 102286
Published: May 6, 2024
Language: Английский
Citations
7
Nature Communications, Journal Year: 2024, Volume and Issue: 15(1)
Published: Aug. 9, 2024
Despite the potential of small molecules and recombinant proteins to enhance efficiency homology-directed repair (HDR), single-stranded DNA (ssDNA) donors, as currently designed chemically modified, remain suboptimal for precise gene editing. Here, we screen biased ssDNA binding sequences repair-related engineer RAD51-preferred into HDR-boosting modules donors. Donors with these exhibit an augmented affinity RAD51, thereby enhancing HDR across various genomic loci cell types when cooperated Cas9, nCas9, Cas12a. By combining inhibitor non-homologous end joining (NHEJ) or HDRobust strategy, modular donors achieve up 90.03% (median 74.81%) efficiency. The targeting endogenous protein enable a chemical modification-free strategy improve efficacy Single-stranded using current design parameters inefficient authors types.
Language: Английский
Citations
7
Advanced Functional Materials, Journal Year: 2024, Volume and Issue: 34(26)
Published: Jan. 9, 2024
Abstract In situ tumor vaccines (ISTVs) hold great potential in immunotherapy, however, three major obstacles, including inadequate endogenous antigen uptake by dendritic cells (DCs), weak T‐cell immune responses, and stubborn immunosuppressive microenvironment (TME), still need to be fully addressed. Herein, a trifecta nanovaccine (TriNV) with TME‐responsive transformable ability is developed tri‐boost antitumor immunity. First, sufficient tumor‐associated antigens (TAAs) are liberated after immunogenic cell death induced via TriNV‐based photoimmunotherapy. the TME, soft‐transformed TriNV improves of TAAs DCs enhance acquired Second, self‐adjuvating released Mn 2+ synergistically promote DC maturation macrophage M1 polarization augmenting stimulator interferon genes activation further amplify responses. Moreover, decomposition MnO 2 within core exhausts glutathione facilitates O release alleviate hypoxia thereby overcoming chemical obstacles TME mitigate immunosuppression. Thus, remarkably eradicates primary tumors inhibits distant metastasis, thus demonstrating as feasible effective ISTV nanoplatform for combating poorly solid tumors.
Language: Английский
Citations
6